18K ice cream cartons recalled for possible plastic contamination
(NewsNation) — Close to 18K of ice cream cartons have been recalled, according to an FDA enforcement report.
The recall was for 22 flavors of ice cream and frozen yogurt available across the United States in late April, after concerns that some tubs may have small pieces of plastic in them.
The flavors recalled included:
Wells Enterprises Rocky Road Flavored Ice Cream
Wells Enterprises Mocha Almond Fudge Ice Cream
Wells Enterprises Peanut Butter 'N Fudge Ice Cream
Wells Enterprises Country Rich Vanilla Ice Cream
Wells Enterprises Scooper Hero Ice Cream
Wells Enterprises Cotton Candy Flavored Ice Cream
Wells Enterprises GFGB Vanilla Bean Flavored Ice Cream
Wells Enterprises Quick Blend Vanilla Flavored Ice Cream
Wells Enterprises Planet Smoothie ZSA Vanilla Fat Free Frozen Yogurt
Wells Enterprises Johnny Rockets Vanilla Flavored Ice Cream
Wells Enterprises BIPC Flavored Ice Cream
Wells Enterprises Vanilla Frozen Yogurt
Wells Enterprises Vanilla Flavored Ice Cream
Wells Enterprises GFGB 12 Percent Vanilla Flavored Ice Cream
Gordon Food Service Gordon's Choice Vanilla Flavored Ice Cream
US Food Vanilla Bean Ice Cream (Madagascar Vanilla)
US Foods Glenview Farms Vanilla Flavored, Chocolate and French Vanilla Ice Cream
Sysco Corporation French Vanilla Ice Cream
Ben E. Keith Foods Valley Vanilla Flavored Ice Cream
Ben E. Keith Foods Ellington Farms Vanilla Flavored Ice Cream
What is diabetes?
The FDA classified the recall as a Class II, which details that the contaminated product could cause 'temporary or medically reversible adverse health consequences, though the risk of serious harm is considered remote.'
There have been no reports of injuries or adverse reactions.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for YOLT-101, an in vivo base editing therapy targeting PCSK9 for the treatment of heterozygous familial hypercholesterolemia (HeFH). "The FDA IND clearance marks a significant milestone for YolTech," said Dr. Yuxuan Wu, Co-founder and CEO of YolTech Therapeutics. "In vivo gene editing represents a new generation of therapeutics—offering one-time, durable solutions for chronic and genetic diseases. We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases. '' About YOLT-101 YOLT-101 is an investigational in vivo base editing therapy designed to be a single-dose treatment to durably reduce blood LDL-C. It is based on YolTech's proprietary adenine base editor, YolBE—specifically hpABE5—which comprises nCas and a novel deaminase evolved from Hafnia paralvei. For delivery, YOLT-101 utilizes YolTech's innovative lipid nanoparticle (LNP) delivery system. Unlike traditional CRISPR/Cas9 systems that rely on DNA double-strand breaks (DSBs), hpABE5 enables precise A•T to G•C base conversion without introducing DSBs, thereby significantly reducing risks of chromosomal abnormalities and off-target effects. YOLT-101 is being evaluated in ongoing investigator-initiated trial (IIT), where it has demonstrated a favorable safety profile and robust LDL-C–lowering effects. For detailed clinical data, please refer to: About Familial Hypercholesterolemia (FH) Familial hypercholesterolemia (FH) is caused by mutations in LDL metabolism-related genes such as LDLR, APOB, and PCSK9. Patients with FH exhibit significantly elevated levels of low-density lipoprotein cholesterol (LDL-C) and a high risk of early-onset atherosclerotic cardiovascular disease (ASCVD). The estimated global prevalence of FH is 1 in 200 to 1 in 250, affecting approximately 34 million individuals worldwide. Current treatment strategies—lifestyle modifications, statins, ezetimibe, PCSK9 inhibitors, lipoprotein apheresis, and even liver transplantation—often fall short in terms of efficacy, tolerability, or patient adherence. This creates a critical unmet need for durable, one-time therapies that can address the root cause of disease. About YolTech YolTech Therapeutics is a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines. Our approach combines innovative gene editing technologies with an advanced lipid nanoparticle (LNP) delivery system, creating a versatile platform designed to address a wide range of serious diseases. Central to our mission is the development of internal capabilities, including end-to-end manufacturing, to ensure the highest standards of quality and scalability. Our lead candidate, targeting ATTR, marks a significant milestone as China's first LNP-mediated in vivo gene editing therapy to enter clinical development. With promising early clinical outcomes, YolTech is also advancing therapies for familial hypercholesterolemia (FH) and primary hyperoxaluria type 1 (PH1). As a company dedicated to transforming the treatment landscape, YolTech continues to push the boundaries of what is possible in gene editing. To learn more, please visit: View original content: SOURCE YolTech Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for YOLT-101, an in vivo base editing therapy targeting PCSK9 for the treatment of heterozygous familial hypercholesterolemia (HeFH). "The FDA IND clearance marks a significant milestone for YolTech," said Dr. Yuxuan Wu, Co-founder and CEO of YolTech Therapeutics. "In vivo gene editing represents a new generation of therapeutics—offering one-time, durable solutions for chronic and genetic diseases. We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases. '' About YOLT-101 YOLT-101 is an investigational in vivo base editing therapy designed to be a single-dose treatment to durably reduce blood LDL-C. It is based on YolTech's proprietary adenine base editor, YolBE—specifically hpABE5—which comprises nCas and a novel deaminase evolved from Hafnia paralvei. For delivery, YOLT-101 utilizes YolTech's innovative lipid nanoparticle (LNP) delivery system. Unlike traditional CRISPR/Cas9 systems that rely on DNA double-strand breaks (DSBs), hpABE5 enables precise A•T to G•C base conversion without introducing DSBs, thereby significantly reducing risks of chromosomal abnormalities and off-target effects. YOLT-101 is being evaluated in ongoing investigator-initiated trial (IIT), where it has demonstrated a favorable safety profile and robust LDL-C–lowering effects. For detailed clinical data, please refer to: About Familial Hypercholesterolemia (FH) Familial hypercholesterolemia (FH) is caused by mutations in LDL metabolism-related genes such as LDLR, APOB, and PCSK9. Patients with FH exhibit significantly elevated levels of low-density lipoprotein cholesterol (LDL-C) and a high risk of early-onset atherosclerotic cardiovascular disease (ASCVD). The estimated global prevalence of FH is 1 in 200 to 1 in 250, affecting approximately 34 million individuals worldwide. Current treatment strategies—lifestyle modifications, statins, ezetimibe, PCSK9 inhibitors, lipoprotein apheresis, and even liver transplantation—often fall short in terms of efficacy, tolerability, or patient adherence. This creates a critical unmet need for durable, one-time therapies that can address the root cause of disease. About YolTech YolTech Therapeutics is a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines. Our approach combines innovative gene editing technologies with an advanced lipid nanoparticle (LNP) delivery system, creating a versatile platform designed to address a wide range of serious diseases. Central to our mission is the development of internal capabilities, including end-to-end manufacturing, to ensure the highest standards of quality and scalability. Our lead candidate, targeting ATTR, marks a significant milestone as China's first LNP-mediated in vivo gene editing therapy to enter clinical development. With promising early clinical outcomes, YolTech is also advancing therapies for familial hypercholesterolemia (FH) and primary hyperoxaluria type 1 (PH1). As a company dedicated to transforming the treatment landscape, YolTech continues to push the boundaries of what is possible in gene editing. To learn more, please visit: View original content: SOURCE YolTech Therapeutics
Yahoo
6 hours ago
- Yahoo
Oral health continues to be a challenge in Arkansas
LITTLE ROCK, Ark. – Brushing, flossing and annual dental checkups are very important, but officials say oral care in Arkansas continues to be a problem. Officials with the ADH Oral Health Program said Arkansas has many rural areas, and access to oral health care for people who live in rural areas can be challenging due to longer driving distances to care and other factors such as insurance coverage. Arkansas also has some counties that have been federally designated as dental provider shortage areas, which means there are not enough dentists to care for the population residing in the county. FDA Signals major shift on fluoride treatments for children Dental Director for Delta Dental of Arkansas, a dental benefits company, Niki Carter says after and during COVID oral health care became bad nationwide. However, last year Arkansas was ranked low for poor oral care. 'Arkansas is 50th in the nation, so we have our work cut for us,' Carter said. Carter explained that one way there's a gap in care has to do with distribution. '60% of dentists practice in only eight of the state's 75 counties and these eight counties represent 40% of the state's population that are all in urban areas,' Carter said. 'Technically, 60% of the population lives in rural areas.' Carter said that's not the only problem, the other issue is a shortage of dentists. 'Technically, there is a shortage of dentists per 100,000 population in our state,' Carter said. Study ranks Arkansas at the absolute bottom for dental health Carter says most dentists want to practice in metropolitan areas, which is why she's glad Lyon College will open the state's first dental school this month. 'One aspect of poor oral health is it affects numerous systemic illnesses,' Carter said. She also says students could go through a loan repayment program helping serve those needed areas. 'New dental students are graduating with $300,000 and $400,000 in debt. Through the repayment program, they will go to these rural areas and practice for a certain amount of time and pay back that loan,' Carter said. Carter says they also partner with multiple companies that provide care to patients, hoping they can help close the gap. One of the partners is Teledentistry, where members have 24/7 access to dental visits. Lyon College holds groundbreaking for first dental school in Arkansas Officials with the Arkansas Department of Health Office of Oral Health also say they're focused on promoting lifelong, optimum oral health for all Arkansans through education and prevention. This includes programming that educates health care providers about the interplay of oral health on systemic health, raising awareness about oral disease and the importance of regular dental care and programming that promotes and supports daily oral health hygiene habits for all ages, particularly children. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
